Marc Ferrante
Impact in
- Genetics top 0.05%
- Inflammatory Bowel Disease
- Mesenchymal stem cell research
- Immunology top 1%
- Biosimilars and Bioanalytical Methods
Papers in
- Genetics 353
- Inflammatory Bowel Disease 351
- Immunology 18
- Biosimilars and Bioanalytical Methods 14
- Co-authors
- Severine A.R.A. Vermeire (251 shared papers)Gert Van Assche (173 shared papers)Paul J. Rutgeerts (72 shared papers)Maja Noman (39 shared papers)Vera Ballet (38 shared papers)Ann Gils (53 shared papers)Ingrid Arijs (25 shared papers)Kristel Van Steen (20 shared papers)
- Journals
- Journal of Crohn s and Colitis (89 papers)Gastroenterology (63 papers)Inflammatory Bowel Diseases (42 papers)Gut (21 papers)Clinical Gastroenterology and Hepatology (21 papers)
- Partner nations
- BelgiumUnited StatesNetherlands
In The Last Decade
Marc Ferrante
419 papers receiving 27k citations
Marc Ferrante's Hit Papers
Peers
Comparison fields: 5 of 149
- Genetics 17.4k
- Immunology 1.7k
- Oncology 1.8k
- Molecular Biology 3.9k
- Health Informatics 139
Countries citing papers authored by Marc Ferrante
This map shows the geographic impact of Marc Ferrante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Ferrante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Ferrante more than expected).
Fields of papers citing papers by Marc Ferrante
This network shows the impact of papers produced by Marc Ferrante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Ferrante. The network helps show where Marc Ferrante may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc Ferrante, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 437 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium Hit paper breakdown → | 2011 | 3042 |
| 2 | A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis Hit paper breakdown → | 2013 | 1592 |
| 3 | Ulcerative colitis Hit paper breakdown → | 2020 | 1293 |
| 4 | Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial Hit paper breakdown → | 2016 | 858 |
| 5 | Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease Hit paper breakdown → | 2015 | 745 |
| 6 | Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease Hit paper breakdown → | 2012 | 693 |
| 7 | Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease Hit paper breakdown → | 2009 | 591 |
| 8 | 2008 | 457 | |
| 9 | 2009 | 431 | |
| 10 | 2008 | 388 | |
| 11 | Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening Hit paper breakdown → | 2019 | 387 |
| 12 | Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study Hit paper breakdown → | 2017 | 385 |
| 13 | 2017 | 358 | |
| 14 | 2016 | 344 | |
| 15 | 2009 | 332 | |
| 16 | Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials Hit paper breakdown → | 2022 | 309 |
| 17 | 2011 | 281 | |
| 18 | 2015 | 277 | |
| 19 | 2019 | 272 | |
| 20 | Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial Hit paper breakdown → | 2022 | 254 |
About Marc Ferrante
Marc Ferrante is a scholar working on Genetics, Immunology, Oncology, Molecular Biology and Public Health, Environmental and Occupational Health, having authored 437 papers that have together received 27.6k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (351 papers), Gut microbiota and health (15 papers), Biosimilars and Bioanalytical Methods (14 papers), Pregnancy and Medication Impact (9 papers), Anorectal Disease Treatments and Outcomes (6 papers), Colorectal Cancer Screening and Detection (5 papers), Pharmaceutical studies and practices (5 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). The work is most often cited by research in Genetics (17.4k citations), Immunology (1.7k citations), Oncology (1.8k citations), Molecular Biology (3.9k citations) and Health Informatics (139 citations). Marc Ferrante has collaborated with scholars based in Belgium, United States and Netherlands. Frequent co-authors include Severine A.R.A. Vermeire, Gert Van Assche, Paul J. Rutgeerts, Maja Noman, Vera Ballet, Ann Gils, Ingrid Arijs, Kristel Van Steen, Hans C. Clevers and Stieneke van den Brink. Their work appears in journals such as Journal of Crohn s and Colitis, Gastroenterology, Inflammatory Bowel Diseases, Gut and Clinical Gastroenterology and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.